Summary & Overview
HCPCS J0901: Vadadustat, oral, 1 mg (ESRD on dialysis)
HCPCS Level II code J0901 denotes Vadadustat, oral, 1 mg, indicated for patients with end-stage renal disease (ESRD) on dialysis. As an HCPCS Level II drug code, J0901 is used by outpatient providers and dialysis facilities to report administration or dispensing of this oral anemia therapy. Nationally, the code is relevant as oral hypoxia-inducible factor prolyl hydroxylase inhibitor therapies expand treatment options for anemia in dialysis-dependent patients and payers establish coverage policies and billing practices.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J0901 represents, how it is used in the clinical context of dialysis-associated anemia, and the typical sites of service where billing occurs. The publication summarizes payer coverage landscape and common billing modifiers when available, provides benchmark-oriented guidance on where J0901 sits within the outpatient dialysis drug billing workflow, and flags areas where data is limited.
Data not available in the input: associated taxonomies, specific ICD-10 diagnoses, related procedure or pharmacy codes, and detailed payer-specific reimbursement rates.
Billing Code Overview
HCPCS Level II code J0901 represents Vadadustat, oral, 1 mg, specified for use in patients with end-stage renal disease (ESRD) on dialysis. This code is used to bill for the drug formulation and strength described.
Service type: Oral pharmaceutical therapy for anemia associated with ESRD on dialysis
Typical site of service: Outpatient clinics, dialysis centers, and other outpatient settings where patients with ESRD receive oral medications as part of dialysis-related care.
Clinical & Coding Specifications
Clinical Context
A 64-year-old patient with end-stage renal disease (ESRD) on maintenance hemodialysis presents for routine nephrology follow-up to manage anemia of chronic kidney disease. The patient is prescribed oral J0901 (vadadustat, 1 mg formulation for ESRD on dialysis) to maintain hemoglobin within target range and reduce transfusion needs. The clinical workflow includes medication reconciliation, review of recent hemoglobin, iron studies (ferritin, transferrin saturation), and blood pressure; initiation or continuation of J0901 with education on dosing and adherence; monitoring labs at baseline and every 2–4 weeks after dose changes until stable; documentation of indication (anemia due to CKD on dialysis) and medical necessity; and coordination with the dialysis unit for medication administration or verification of patient-reported oral dosing. Pharmacy billing uses HCPCS Level II code J0901 for the drug supply; if furnished in a dialysis facility, facility and professional roles are documented and appropriate modifiers applied for billing scenarios such as outpatient administration in the dialysis unit versus patient self-administered at home.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier |